Cognetivity Neurosciences Unveils Groundbreaking Research on Cognition and Sleep, Extends Collaboration With University of Oxford
Cognetivity Neurosciences Unveils Groundbreaking Research on Cognition and Sleep, Extends Collaboration With University of Oxford
Company presents key data on measuring impact of sleep disorders on brain health; University of Oxford extends collaboration on monitoring changes in cognition of older adults
該公司提供了衡量睡眠障礙對大腦健康影響的關鍵數據；牛津大學擴大了在監測老年人認知變化方面的合作
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the "Company" or "Cognetivity"), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce important validation results for the use of its CognICA technology in measuring the impact of changes in sleep patterns on brain health, as well as further collaboration with Oxford University to detect the earliest signs of impairment associated with diseases such as Alzheimer's.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年3月23日)-認知神經科學有限公司。(CSE：CGN)(OTCQB：CGNSF)(FSE：1UB)(“公司”或“認知力”)創建了用於醫療、商業和消費環境的獨特腦健康篩查平臺的科技公司很高興地宣佈，其CognICA技術用於測量睡眠模式變化對大腦健康的影響的重要驗證結果，以及與牛津大學的進一步合作，以檢測與阿爾茨海默氏症等疾病相關的早期損害跡象。
Cognetivity's Chief Innovation Officer, Dr Seyed-Mahdi Khaligh-Razavi will be presenting results on recent work on the impact of sleep on brain health at the 10th Congress of Asian Sleep Research (ASRS) on March 31st in Istanbul, Turkey. Normal sleep is essential for overall brain health and well-being, including cognition and memory formation. However, sleep disorders are highly prevalent and may affect 30-48% of older adults. To date, evaluating cognitive function, both subjectively and objectively, can be cumbersome and costly, but tracking cognitive performance in sleep disorders can help identify the appropriate frequency and duration of treatment, as well as optimize proposed lifestyle changes to meet individual needs.
Cognetivity首席創新官Seed-Mahdi Khaligh-Razavi博士將於3月31日在土耳其伊斯坦布爾舉行的第10屆亞洲睡眠研究大會(ASR)上展示最近關於睡眠對大腦健康影響的研究成果。正常的睡眠對整個大腦的健康和幸福至關重要，包括認知和記憶的形成。然而，睡眠障礙非常普遍，可能會影響30-48%的老年人。到目前為止，主觀和客觀地評估認知功能可能會很麻煩，成本也很高，但跟蹤睡眠障礙的認知表現可以幫助確定適當的治療頻率和持續時間，以及優化擬議的生活方式改變，以滿足個人需求。
At the conference Dr Khaligh-Razavi will present results showing the application of CognICA in tracking cognitive performance in relation to sleep. For patients with sleep disorders, the impact of treatment on their cognition, as measured quantitatively by Cognetivity's CognICA technology, can be easily used to identify the optimal frequency and duration of treatment for each person. This then allows individuals to improve their brain health by improving their sleep patterns.
在會議上，Khaligh-Razavi博士將展示研究結果，展示CognICA在跟蹤與睡眠有關的認知表現方面的應用。對於睡眠障礙患者，通過Cognetivity的CognICA技術定量衡量治療對他們認知的影響，可以很容易地確定每個人的最佳治療頻率和持續時間。然後，這就允許個人通過改善睡眠模式來改善他們的大腦健康。
This can open up a huge market for Cognetivity, with the sleep technology devices market expected to grow from 15 billion in 2021 to over 67 billion in 2030, and growing interest in consumers in tracking sleep and measuring the impact on performance and health.
這可以為Cognetivity打開一個巨大的市場，睡眠技術設備市場預計將從2021年的150億增長到2030年的超過670億，而且消費者對跟蹤睡眠並衡量其對性能和健康的影響的興趣日益濃厚。
Cognetivity also announces the extension of its partnership with Oxford University on monitoring the cognition of individuals at risk of developing dementia. The purpose of the project is to detect the earliest signs of changes to allow the earliest possible intervention to preserve brain function and have the greatest positive impact of treatment. The study works with the Great Minds cohort, run by Dementia Platform UK, a business and research consortium which includes AstraZeneca, GSK, Janssen and Cognetivity as partners.
Cognetivity還宣佈延長其與牛津大學的合作夥伴關係，監測有患痴呆症風險的個人的認知。該專案的目的是發現最早的變化跡象，以便盡可能早地進行幹預，以保存大腦功能，並對治療產生最大的積極影響。這項研究與英國痴呆症平臺運營的Great Minds隊列合作，這是一個商業和研究聯盟，合作夥伴包括阿斯利康、葛蘭素史克、揚森和Cognetivity。
Cognetivity's CEO Dr Sina Habibi commented "We are always delighted to share results from our ongoing R&D activities, especially when they open up markets as significant as managing sleep patterns, an area of growing concern for individuals and clinicians worldwide." He added "When we add this to the expansion of our collaboration with such a fantastic academic partner as Oxford University, it shows our continued ability to deliver cutting edge research that demonstrates new use cases for our technology and its relevance and suitability for next-generation healthcare and consumer wellness."
Cognetivity的首席執行官Sina Habibi博士評論說：“我們總是很高興分享我們正在進行的研發活動的結果，特別是當他們打開了像管理睡眠模式這樣重要的市場時，這是一個越來越受到全球個人和臨床醫生關注的領域。”他補充說：“當我們將這一點加入到我們與牛津大學這樣出色的學術合作夥伴的合作中時，這表明我們繼續有能力提供尖端研究，展示我們技術的新用例，以及它對下一代醫療保健和消費者健康的相關性和適宜性。”
Cognetivity also announces that, effective immediately, Mr. David Velisek has resigned as a director of the Company in order to concentrate on other projects. Mr. Velisek has been a director of the Company since December 11, 2015 and in that time has provided significant value that has materially contributed to the strategic direction, growth, and success of the Company. The Company extends its sincere gratitude to Mr. Velisek for his service and contributions he has made to the Company, and wishes him every success in his future endeavors.
認知科技同時宣佈，自即日起，David·韋利塞克先生已辭去公司董事的職務，以便專注於其他專案。韋利塞克先生自2015年12月11日起擔任公司董事一職，在此期間為公司的戰略方向、增長和成功做出了重大貢獻。本公司衷心感謝韋利塞克先生為本公司所做的服務和貢獻，並祝願他在未來的事業中取得圓滿成功。
The Company also announces that it has entered into debt settlement agreements (each, a "Debt Settlement Agreement") with certain creditors of the Company to issue an aggregate of 816,555 common shares ("Common Shares") in the capital of Company ("Debt Shares") at a deemed price of $0.325 per Debt Share to settle an aggregate of approximately $265,380 of outstanding debt (the "Shares for Debt Transaction"). 658,892 of such Common Shares (the "Sawyer Shares") were issued to Dr. Thomas Sawyer, Chief Operating Officer, Chief Financial Officer, Corporate Secretary and a director of the Company.
本公司還宣佈，它已達成債務解決協定(每個、一個或多個)債務清償協定“)與本公司若干債權人發行合共816,555股普通股(”普通股“)公司資本(”債務股“)，每股債務0.325美元，以了結總額約265,380美元未償債務(“用於債務交易的股票“)。658,892股此類普通股(”Sawyer股份“)頒發給公司首席運營官、首席財務官、公司祕書和董事的託馬斯·索耶博士。
The issuance of the Sawyer Shares to Dr. Sawyer constitutes a "related party transaction" as this term is defined in Multilateral Instrument 61-101 Protection of Minority Securityholders in Special Transactions ("MI 61-101"). Pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company is exempt from obtaining a formal valuation and minority shareholder approval as neither the fair market value of the amounts owed to Dr. Sawyer nor the Sawyer Shares exceeds 25% of the Company's market capitalization.
向Sawyer博士發行Sawyer股票構成多邊文書61-101中定義的“關聯方交易”特殊交易中少數股證券持有人的保護(“米其林61-101根據MI 61-101第5.5(A)及5.7(1)(A)條，本公司獲豁免獲得正式估值及小股東批准，因為欠Sawyer博士及Sawyer股份的款項的公平市值均不超過本公司市值的25%。
No new insiders nor control persons were created as a result of the issuance of the Debt Settlement Shares. The Company did not file a material change report more than 21 days before the expected closing of the related party transaction as the details of the applicable Debt Settlement Agreement were not finalized until closer to the closing date of the transaction, and the Company wanted to close the transaction as soon as possible as part of broader efforts to reduce liabilities on the balance sheet.
並無因發行債務清償股份而產生新的內部人士或控制人。本公司並未於關聯方交易預期完成前21天提交重大變動報告，因為適用的債務清償協定的細節直到接近交易完成日期才最終敲定，而本公司希望儘快完成交易，作為減少資產負債表負債的更廣泛努力的一部分。
The Company also announces the issuance of an aggregate of 356,875 Common Shares to certain advisors, employees and consultants in accordance with the terms of their agreements.
該公司還宣佈，根據某些顧問、員工和顧問的協定條款，向他們發行總計356,875股普通股。
All Debt Settlement Shares and Common Shares issued to a certain advisor, employees and consultants are subject to a statutory hold period expiring on July 24, 2023, in accordance with applicable securities laws and the policies of the Canadian Securities Exchange.
根據適用的證券法和加拿大證券交易所的政策，向某一顧問、員工和顧問發行的所有債務清償股票和普通股均受2023年7月24日到期的法定持有期的約束。
None of the foregoing securities have been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any applicable state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) or persons in the United States absent registration or an applicable exemption from such registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the foregoing securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
上述證券均未或將不會根據修訂後的《1933年美國證券法》(the1933年法案“)或任何適用的州證券法，不得在美國或為美國人(如1933年法案下的S規則所界定)或在美國的人的賬戶或利益而出售，除非進行登記或獲得適用的豁免。本新聞稿不構成出售要約或徵求購買要約，在任何司法管轄區內，上述證券的出售、招攬或出售都不會被視為違法。
About Cognetivity Neurosciences Ltd.
關於認知性神經科學有限公司
Cognetivity is a technology company that has created a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the USA, UK, Europe and the Middle East, with regulatory approval for other regions planned for 2023.
Cognetivity是一家技術公司，它創建了一個認知測試平臺，用於醫療、商業和消費環境。Cognetivity的ICA使用人工智慧和機器學習技術，通過測試大腦大片區域的表現來幫助檢測認知障礙的最早跡象。ICA目前可在美國、英國、歐洲和中東用於臨床，其他地區的監管批准計劃於2023年進行。
ON BEHALF OF THE BOARD
我代表董事會
"Sina Habibi"
Sina Habibi
《新浪哈比比》
新浪哈比比
Chief Executive Officer and Director
董事首席執行官兼首席執行官
FORWARD-LOOKING STATEMENTS:
前瞻性陳述：
Certain statements included in this news release constitute forward-looking information or statements (collectively, "forward-looking statements"), including those identified by the expressions "anticipate", "assume" "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company's forward-looking statements.
本新聞稿中包含的某些陳述構成前瞻性資訊或陳述(統稱為“前瞻性陳述”)，包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及與公司或其管理層有關的類似表述。前瞻性陳述不是歷史事實，但反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證，涉及難以預測的風險、不確定因素和假設。此類陳述基於當前預期和各種估計、因素和假設，涉及已知和未知的風險、不確定性和其他因素。這些陳述和資訊是基於對目前和未來的業務戰略以及公司未來運營環境的許多假設。除非法律要求，否則公司不承擔更新或修改前瞻性資訊以反映新事件或新情況的責任。讀者不應過分依賴該公司的前瞻性陳述。
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性承擔責任。
For further information: Please visit: or contact: info@cognetivity.com; for media inquiries please contact pr@cognetivity.com
有關更多資訊，請訪問：請訪問：或聯繫：info@cognetivity.com；媒體查詢請聯繫pr@cognetivity.com
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。